# Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

> **NCT00493181** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Leukemia
- Chronic Myelogenous Leukemia
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Interleukin-11 (IL-11 or Neumega)

## Key facts

- **NCT ID:** NCT00493181
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2012-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00493181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00493181, "Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00493181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*